Trinity Biotech plc unveiled its new flagship product, CGM+, on July 24, 2025, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. CGM+ is an AI-native continuous glucose monitoring (CGM) system that combines multi-sensor data and real-time analytics to meet the evolving demands of AI-powered healthcare and wellness. The device is in the later stages of development.
CGM+ integrates an ultra-thin minimally invasive electrochemical glucose sensor with continuous monitoring of heart activity, body temperature, and physical activity within a single, sleek, and user-friendly modular wearable device. This multimodal data stream is optimized for real-time AI analysis, enabling a deeper, more contextual understanding of metabolic and physiological health. The proprietary needle-free glucose sensor technology facilitates the collection of these expanded data points.
The innovative design of CGM+ utilizes reusable components to reduce disposable waste and significantly lower the cost of care compared to current leading market products. Trinity Biotech anticipates the commercial launch of CGM+ in mid-2026, expecting multiple revenue streams including device sales, AI analytics subscriptions, and strategic partnerships. This platform aims to position Trinity Biotech at the forefront of a new category of intelligent wearables, extending beyond traditional diagnostics into chronic disease management, digital health, and consumer wellness.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.